欢迎来到三一文库! | 帮助中心 三一文库31doc.com 一个上传文档投稿赚钱的网站
三一文库
全部分类
  • 研究报告>
  • 工作总结>
  • 合同范本>
  • 心得体会>
  • 工作报告>
  • 党团相关>
  • 幼儿/小学教育>
  • 高等教育>
  • 经济/贸易/财会>
  • 建筑/环境>
  • 金融/证券>
  • 医学/心理学>
  • ImageVerifierCode 换一换
    首页 三一文库 > 资源分类 > PPT文档下载  

    antianginaldrugs抗心绞痛药 ppt课件.ppt

    • 资源ID:3026371       资源大小:3.15MB        全文页数:30页
    • 资源格式: PPT        下载积分:6
    快捷下载 游客一键下载
    会员登录下载
    微信登录下载
    三方登录下载: 微信开放平台登录 QQ登录   微博登录  
    二维码
    微信扫一扫登录
    下载资源需要6
    邮箱/手机:
    温馨提示:
    用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)
    支付方式: 支付宝    微信支付   
    验证码:   换一换

    加入VIP免费专享
     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    antianginaldrugs抗心绞痛药 ppt课件.ppt

    Part 6 Antianginal Drugs,Organic nitrates receptor blockers Calcium channel blockers,Coronary vessels: blood supply for the heart,1. OVERVIEW,Coronary atherosclerosis: cause of cardiac ischemia,Distribution of coronary arteries in the heart,Ischemia (angina pectoris ): imbalance between oxygen demand and supply,Classification of angina pectoris: Exertional angina (劳累性心绞痛) Stable angina (稳定性心绞痛) Initial onset angina (初发型心绞痛) Accelerated angina (恶化性心绞痛) Spontaneous angina (自发性心绞痛) Angina decubitus (卧位型心绞痛) Variant or vasospastic angina (变异性痉挛性心绞痛) Acute coronary insufficiency (急性冠脉功能不全) Postinfarction angina (梗死后心绞痛) Mixed angina (混合性心绞痛) Unstable angina (不稳定性心绞痛),1. OVERVIEW,Myocardial oxygen demand is chiefly determined by: Contractility Heart rate Wall tension Preload (venous return ) Afterload (arteriolar resistance),1. OVERVIEW,preload,afterload,Myocardial oxygen demand is diminished by: Reducing contractility Reducing heart rate Reducing the preload Reducing the afterload,1. OVERVIEW,Wall tension ,1. OVERVIEW,Myocardial oxygen supply is chiefly determined by: AV oxygen difference Regional myocardial distribution coronary blood flow: vascular resistance, artery pressure,Effects of antianginal drugs: Reducing oxygen demands Reducing heart rate and contractility Dilating systemic arteries and veins ( wall tension by lowering heart loads) Increasing oxygen supply Dilating conduct coronary arteries ( coronary blood flow) Promoting regional distribution ( in ischemic regions) Others: Anti- platelet coagulation and thrombus formation,1. OVERVIEW,2.1 Nitrates Nitroglycerin (硝酸甘油) A. Pharmacological actions Dilating vessels and reducing heart loads wall tension ; reflex tachycardia Redistribution of coronary circulation dilating conduct artery: collateral circulation reducing wall tension: blood flow in ischemic subendocardial area ,2. Antianginal drugs,Influence of organic nitrates and dipyridamole on the blood supply of ischemic area,2. Antianginal drugs,Mechanism of the effect of nitroglycerin and other nitrates,2. Antianginal drugs,Mechanism of the effect of nitroglycerin and other nitrates,B. Clinical uses Angina pectoris: all kinds, especially stable type Heart failure:reducing heart loads due to vasodilation C. Adverse reactions Increase in heart rate and contractility Symptoms due to vasodilation: headache, flash, postural hypotension, collapse, ect. Others: methaemoglobinaemia(高铁血红蛋白) Tolerance : avoiding steady-state plasma concentration; supplement of agents containing SH (captopril),2. Antianginal drugs,2.1 Other nitrates Isosorbide dinitrate (硝酸异山梨酯) Isosorbide-5-mononirate (5-硝酸异山梨酯) Compared with nitroglycerin: Similar but weaker effect Acting slowly but lasting longer Larger individual variation and more adverse effects,2. Antianginal drugs,2.2 receptor blockers A. Pharmacological action Reducing oxygen demand: heart rate and contractility Increasing oxygen supply: diastolic period : perfusion time vascular tone in normal regions : blood flow in ischemic regions Others: Improving myocardial metabolism Inhibiting coagulation of platelets,2. Antianginal drugs,B. Clinical uses stable and unstable pectoris, especially associated with hypertension or arrhythmias, even with myocardial infarction; but not used for variant angina pectoris C. Notes Dose individualization: starting from small dose Withdraw gradually and slowly: symptom rebound Combination with nitroglycerin,2. Antianginal drugs,2.3 Calcium channel blockers,2. Antianginal drugs,2.3 Calcium channel blockers A. Pharmacological actions Reducing myocardial oxygen remand: heart loads : nifedipine heart rate and contractility : verapamil and diltiazem Increasing myocardial blood supply Protecting ischemic myocardial cells Inhibiting coagulation of platelets,2. Antianginal drugs,Actions of calcium channel blockers,B. Clinical uses stable and variant type: nifedipine, verapamil, diltiazem unstable type: verapamil, diltiazem,2. Antianginal drugs,Actions of DHP (like nifedipine) are similar to those of nitroglycerin Actions of verapamil and diltiazem are similar to those of blockers,2.4 Other drugs ACEIs (血管紧张素转化酶抑制药) Treating hypertension and preventing ischemic heart disease Reducing heart loads Inhibiting cardial remodeling Nicorandil (尼可地尔) Opening ATP-sensitive K+ channel (KATP) Lowering intracellular Ca2+ Providing NO (like nitroglycerin) Inducing ischemic preconditioning,2. Antianginal drugs,Molsidomine (吗多明) Inhibiting adenosine uptake and cAMP degradation Inhibiting pletelet aggregation Promoting collateral circulation after long-term use Dipyridamole (双嘧达莫,潘生丁) Inhibiting adenosine uptake and cAMP degradation Inhibiting pletelet aggregation Promoting collateral circulation after long-term use,2. Antianginal drugs,nitroglycerin blockers Ca2+ antagonists combination* Heart rate Contractility / Wall tension / / Oxygen demand Blood pressure : increase, : markedly increase; : decrease, : markedly decrease; : variable according to the dose and effect of each drug ; * blockers combined with nitroglycerin or Ca2+ antagonists (nifedipine; combination with verapamil/diltiazem not be recommendated) Caution: Combination may potentiate the antianginal effects, but may induce severe hypotension,3. Summary of antianginal drugs,Sammary,Cardiovascular pharmacology,Overview of Cardiovascular Diseases,Common Cardiac Diseases Abnormal contractility:Heart failures Abnormal rhythms:Arrhythmias Abnormal blood supply:Ischemic heart diseases Myocardial disorders Common vascular diseases Abnormal systematic resistance:Hypertension Dysfunction of coronary vessels:Coronary vascular diseases Dysfunction of cerebral vessels:Cerebral ischemia, hemorrhage Dysfunction of pulmonary vessels:Pulmonary hypertension Dysfunction of peripheral vessels: Peripheral vascular disorder Arteriosclerosis: basis of most CVS diseases,Overview of Cardiovascular Drugs,Classification based on target organs/tissues Heart:Heart failures, arrhythmias, cardiac ischemia Vessels:Vasodilatation, vasoconstriction, arteriosclerosis Classification based on the mechanisms Ion channels:Ca2+, Na+, K+ channels Receptors:Adrenoceptors, AT1 receptors, etc. Enzymes:ACEI, Na+-K+-ATPase, HMG-CoA reductase Others:Diuretics,Cardiovascular Drugs,Antiarrhthemic drugs Classification; Typical drugs and their properties Antihypertensive drugs Classification; Properties of 6 main drug classes Drugs for treating heart failure Classification; ACEIs, blockers, cardiac glycoide Antiatheroscleotic drugs HMG CoA reductase inhibitors (statins) Antianginal drugs Nitroglycerin; blockers; Ca2+ antagonists,

    注意事项

    本文(antianginaldrugs抗心绞痛药 ppt课件.ppt)为本站会员(本田雅阁)主动上传,三一文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知三一文库(点击联系客服),我们立即给予删除!

    温馨提示:如果因为网速或其他原因下载失败请重新下载,重复下载不扣分。




    经营许可证编号:宁ICP备18001539号-1

    三一文库
    收起
    展开